{"filing":{"accession_number":"0001437749-26-022880","cik":"0001019034","ticker":"BKYI","company_name":"BIO KEY INTERNATIONAL INC","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"bkyi20260706c_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1019034/000143774926022880/bkyi20260706c_8k.htm"},"events":[{"id":16338,"run_id":14592,"accession_number":"0001437749-26-022880","anchor_item_number":"7.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"summary":"BIO-key's disclosure announces the reinstatement of trading on Nasdaq Capital Market following a June 16th hearing where the Nasdaq Hearings Panel determined the Company \"has regained compliance with the continued listing standards, including minimum bid price and SEC filing requirements.\" This directly addresses a delisting risk event—the company had previously been subject to a trading halt due to non-compliance with listing standards and has now resolved that issue. The materiality is clear: trading suspension and reinstatement materially affect investor access to the stock and the company's market standing.","company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14412,"accession_number":"0001437749-26-022880","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"BIO-key's disclosure announces the reinstatement of trading on Nasdaq Capital Market following a June 16th hearing where the Nasdaq Hearings Panel determined the Company \"has regained compliance with the continued listing standards, including minimum bid price and SEC filing requirements.\" This directly addresses a delisting risk event—the company had previously been subject to a trading halt due to non-compliance with listing standards and has now resolved that issue. The materiality is clear: trading suspension and reinstatement materially affect investor access to the stock and the company's market standing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:17:42.432214+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14412,"accession_number":"0001437749-26-022880","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"BIO-key's disclosure announces the reinstatement of trading on Nasdaq Capital Market following a June 16th hearing where the Nasdaq Hearings Panel determined the Company \"has regained compliance with the continued listing standards, including minimum bid price and SEC filing requirements.\" This directly addresses a delisting risk event—the company had previously been subject to a trading halt due to non-compliance with listing standards and has now resolved that issue. The materiality is clear: trading suspension and reinstatement materially affect investor access to the stock and the company's market standing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:17:42.432214+00:00","company_name":"BIO KEY INTERNATIONAL INC","ticker":"BKYI","filing_date":"2026-07-07"}]}